Cargando…

A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine

Rifapentine is a rifamycin used to treat tuberculosis. As is the case for rifampin, plasma exposures of rifapentine are associated with the treatment response. While concomitant food intake and HIV infection explain part of the pharmacokinetic variability associated with rifapentine, few studies hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Francis, Jose, Zvada, Simbarashe P., Denti, Paolo, Hatherill, Mark, Charalambous, Salome, Mungofa, Stanley, Dawson, Rodney, Dorman, Susan, Gupte, Nikhil, Wiesner, Lubbe, Jindani, Amina, Harrison, Thomas S., Olagunju, Adeniyi, Egan, Deirdre, Owen, Andrew, McIlleron, Helen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2019
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437540/ https://www.ncbi.nlm.nih.gov/pubmed/30670438 http://dx.doi.org/10.1128/AAC.01964-18

Ejemplares similares

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
por: Rockwood, Neesha, et al.
Publicado: (2016)

Isolation and characterization of arylacetamide deacetylase in cynomolgus macaques
por: UNO, Yasuhiro, et al.
Publicado: (2015)

Arylacetamide Deacetylase Is Involved in Vicagrel Bioactivation in Humans
por: Jiang, Jinfang, et al.
Publicado: (2017)

Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin‐resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2022)

Validation and application of a quantitative liquid chromatography tandem mass spectrometry assay for the analysis of rifapentine and 25-O-desacetyl rifapentine in human milk
por: Mkhize, Buyisile, et al.
Publicado: (2022)

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2021)

Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings
por: Abdissa, Alemseged, et al.
Publicado: (2014)

Characterization, comparative, and functional analysis of arylacetamide deacetylase from Gnathostomata organisms
por: Diaz-Vidal, Tania, et al.
Publicado: (2022)

Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

Signature of arylacetamide deacetylase expression is associated with prognosis and immune infiltration in ovarian cancer
por: Feng, Jianyang, et al.
Publicado: (2022)

Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children
por: Bienczak, Andrzej, et al.
Publicado: (2017)

Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus‐associated tuberculosis
por: Schutz, Charlotte, et al.
Publicado: (2020)

Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
por: Moultrie, Harry, et al.
Publicado: (2015)

Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis
por: van der Laan, Louvina E., et al.
Publicado: (2021)

Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy
por: Naiker, Suhashni, et al.
Publicado: (2014)

Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis
por: Abdelgawad, Noha, et al.
Publicado: (2022)

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
por: Mathad, Jyoti S, et al.
Publicado: (2021)

Pharmacometrics: Opportunity for Reducing Disease Burden in the Developing World: The Case of Africa
por: Pillai, G, et al.
Publicado: (2013)

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
por: Zhang, C, et al.
Publicado: (2010)

Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania
por: Denti, Paolo, et al.
Publicado: (2015)

Population pharmacokinetics of ethambutol in African children: a pooled analysis
por: Tikiso, Tjokosela, et al.
Publicado: (2022)

Impact of AADAC gene expression on prognosis in patients with Borrmann type III advanced gastric cancer
por: Wang, Yufei, et al.
Publicado: (2022)

Copper-catalyzed transformation of alkyl nitriles to N-arylacetamide using diaryliodonium salts
por: Sallio, Romain, et al.
Publicado: (2021)

Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment
por: Shiau, Stephanie, et al.
Publicado: (2014)

Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis
por: Ngwalero, Precious, et al.
Publicado: (2021)

Association of Genetic Variation in the 3'UTR of LHX6, IMMP2L, and AADAC With Tourette Syndrome
por: Pagliaroli, Luca, et al.
Publicado: (2020)

Evaluation of gene expression of PLEKHS1, AADAC, and CDKN3 as novel genomic markers in gastric carcinoma
por: Abdel-Tawab, Marwa Sayed, et al.
Publicado: (2022)

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy
por: Svensson, Elin M., et al.
Publicado: (2017)

Rifapentine-Proliposomes for Inhalation: In Vitro and In Vivo Toxicity
por: Patil-Gadhe, Arpana A., et al.
Publicado: (2014)

Simplifying Rifapentine Dosing for Tuberculosis Treatment and Prevention
por: Podany, Anthony T.
Publicado: (2020)

Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis
por: Shenje, Justin, et al.
Publicado: (2015)

Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications
por: Court, R., et al.
Publicado: (2018)

Current research toward optimizing dosing of first-line antituberculosis treatment
por: McIlleron, Helen, et al.
Publicado: (2018)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Allelic and genotypic frequencies of NAT2, CYP2E1, and AADAC genes in a cohort of Peruvian tuberculosis patients
por: Levano, Kelly S., et al.
Publicado: (2021)

Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure–response relations from two phase II clinical trials
por: Savic, RM, et al.
Publicado: (2017)

N-Arylacetamide derivatives of methyl 1,2-benzothiazine-3-carboxylate as potential drug candidates for urease inhibition
por: Hina, Sajila, et al.
Publicado: (2023)

AADAC protects colorectal cancer liver colonization from ferroptosis through SLC7A11-dependent inhibition of lipid peroxidation
por: Sun, Rongquan, et al.
Publicado: (2022)

Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis
por: Rockwood, Neesha, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0jgsvpj2k3lptlivdpsocrtnls